Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
cbdMDYCBD +0.77%37 3-Year EBITDA Growth Rate is 89.80% as of Jun. 2026, which is 143% above its 10-year median of 37.00. GuruFocus rates YCBD with a GF Score™ of 37/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 808 Drug Manufacturers companies, cbdMD ranks better than 96.66% on this metric.
During the past 12 months, cbdMD's average EBITDA Per Share Growth Rate was -107.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 89.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 75.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of cbdMD was 89.80% per year. The lowest was -49.50% per year. And the median was 37.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
cbdMD 3-Year EBITDA Growth Rate Related Terms
YCBD vs SNOA, CVSI, AKAN: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, cbdMD's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
cbdMD 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, cbdMD's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where cbdMD's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 89.80% mean?
cbdMD (YCBD) has a 3-Year EBITDA Growth Rate of 89.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for cbdMD and its competitors. This is 143% above median its historical median of 37.00. According to the industry distribution chart, cbdMD ranks #27 out of 808 companies in the Drug Manufacturers industry, placing it in the top 3.3%.
Is cbdMD's 3-Year EBITDA Growth Rate too high?
cbdMD's current 3-Year EBITDA Growth Rate of 89.80% is 143% above median its 10-year median of 37.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. cbdMD's value of 89.80% is 920.5% above this industry median. Based on the distribution chart, cbdMD ranks #27 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, cbdMD has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does cbdMD's 3-Year EBITDA Growth Rate compare to SNOA and CVSI?
According to the Drug Manufacturers industry distribution chart, cbdMD ranks #27 out of 808 companies for 3-Year EBITDA Growth Rate. This places cbdMD in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. cbdMD's value of 89.80% is 920.5% above this benchmark. While the company's 10-year median is 37.00 vs. the industry median of 8.80, cbdMD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. cbdMD's current 3-Year EBITDA Growth Rate of 89.80% is 920.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for cbdMD and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. cbdMD's current 3-Year EBITDA Growth Rate is 89.80%, which is 143% above median its own 10-year median of 37.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is cbdMD stock overvalued right now?
Based on GuruFocus' analysis, cbdMD (YCBD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $0.51 — trading 218.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 89.80%, which is 143% above median its 10-year median of 37.00 and 920.5% above the Drug Manufacturers industry median of 8.80. cbdMD's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For cbdMD (YCBD), the current 3-Year EBITDA Growth Rate is 89.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is cbdMD (YCBD) Overvalued in 2026?
Based on GuruFocus' analysis, cbdMD stock appears to be overvalued.
The current stock price of $0.51 is trading 218.1% above its estimated GF Value™ of $0.16.
GuruFocus considers cbdMD to be Significantly Overvalued.
Key valuation signals for YCBD:
3-Year EBITDA Growth Rate: 89.80% (143% above median its 10-year median of 37.00)
GF Value™: $0.16 vs. price of $0.51 (218.1% above fair value)
Industry Position: 920.5% above the Drug Manufacturers median (#27 of 808)
No single metric tells the full story. See the YCBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
37GF Score
Get the complete analysis for YCBD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YCBD has been successfully added to your 
